English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Conference Paper

A novel epigenetic resistance mechanism to the FLT3 inhibitor PK412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML).

MPS-Authors
/persons/resource/persons185577

Pan,  K. T.
Research Group of Bioanalytical Mass Spectrometry, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons15947

Urlaub,  H.
Research Group of Bioanalytical Mass Spectrometry, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Göllner, S., Agrawal-Singh, S., Oellerich, T., Schenk, T., Rohde, C., Klein, H. U., et al. (2016). A novel epigenetic resistance mechanism to the FLT3 inhibitor PK412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML). Haematologica, 101(Suppl. 1), 166-166.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002B-2E82-9
Abstract
There is no abstract available